{"filings":[{"id":973087,"accession_number":"0001193125-26-265858","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2026-06-10T20:15:18+00:00","items":["5.07"],"status":"ready","headline":"Maze Therapeutics shareholders re-elect two directors, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 44,660,029 shares (89.75% of outstanding) present at June 8 meeting.","Jason Coloma re-elected with 35,792,536 votes for, 5,926,467 withheld.","Neil Kumar re-elected with 34,056,425 votes for, 7,662,578 withheld.","Ratification of Ernst & Young as auditor passed: 44,557,778 for, 728 against.","No broker non-votes on auditor ratification; 2,941,026 broker non-votes on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":611997,"accession_number":"0001193125-26-237199","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2026-05-22T21:24:41+00:00","items":["5.02"],"status":"ready","headline":"Maze Therapeutics SVP Finance Amy Bachrodt to resign effective June 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amy Bachrodt resigns as SVP, Finance, effective June 1, 2026.","Resignation not related to any disagreement with the company.","CFO Misbah Tahir will assume principal accounting officer role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40325,"accession_number":"0001193125-26-219398","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2026-05-12T20:07:51+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maze Q1 net loss $24.2M; MZE829 reduces proteinuria 35.6% in Phase 2 AMKD trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["MZE829 Phase 2 HORIZON: 35.6% mean uACR reduction at week 12 in broad AMKD; 50% of patients had >30% reduction; no serious AEs.","In severe FSGS subgroup, MZE829 achieved 61.8% mean uACR reduction; in non-diabetic AMKD, 48.6% reduction.","Cash $362.9M at March 31, 2026; April 2026 raised ~$150M in offering plus $20M milestone from Shionogi; runway into 2029.","Net loss $24.2M ($0.45/share) vs $32.8M ($1.15) YoY; license revenue $20M; R&D $34.1M, G&A $12.4M.","MZE782 Phase 2 in PKU to start mid-2026 with topline data in 2027; Phase 2 in CKD expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":20000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96129,"accession_number":"0001193125-26-170701","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Maze Therapeutics prices $150M registered offering; net proceeds ~$144.7M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 5,540,000 shares at $23.50/share and 850,000 pre-funded warrants at $23.499 each.","Net proceeds of ~$144.7M to fund R&D for MZE829 (AMKD) and MZE782 (PKU, CKD) and general corporate purposes.","Expected to close April 23, 2026; Leerink Partners LLC is sole underwriter.","Participants include Farallon, T. Rowe Price, Frazier Life Sciences, Janus Henderson, and others.","Cash runway extended into 2029 based on current business plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109758,"accession_number":"0001193125-26-122774","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Maze Q4 net loss $34.6M; MZE829 Phase 2 35.6% uACR drop; Neil Kumar joins board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $34.6M in Q4, $131.1M for FY2025; cash $360M provides runway into 2028.","MZE829 Phase 2 HORIZON: mean uACR reduction 35.6% at week 12; 50% patients >30% reduction.","FSGS subgroup 61.8% mean uACR reduction; non-diabetic AMKD 48.6%; well-tolerated, no serious AEs.","Neil Kumar (BridgeBio CEO) appointed to board effective March 27, 2026; receives option grant.","Plans to advance MZE829 to pivotal program; MZE782 Phase 2 trials in PKU and CKD expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109757,"accession_number":"0001193125-26-037747","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["1.01","1.02","2.03"],"status":"ready","headline":"Maze Therapeutics enters $200M Hercules Capital term loan facility; initial $40M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Up to $200M senior secured term loan from Hercules Capital; initial $40M (Tranche 1A) funded Feb 4, 2026.","Interest rate based on WSJ prime rate with floors 7.95%–9.25%; interest-only period up to 60 months with milestones.","Maturity Feb 1, 2031; prepayment premiums up to 3% within first 12 months, plus exit fee of 3.95%–6.45%.","Covenants include minimum cash requirement of 50% of outstanding loan unless market cap >$450M or >$750M.","Prior Banc of California loan terminated and security released concurrent with this facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126284,"accession_number":"0001193125-25-269624","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maze Q3 net loss $30.1M; cash $383.9M; MZE782 Phase 1 positive; Phase 2 start 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.1M for Q3 2025 vs $24.8M loss in Q3 2024; zero license revenue.","Cash, equivalents and marketable securities $383.9M as of Sep 30, 2025; runway into 2028 after $150M private placement.","MZE782 Phase 1 positive: well-tolerated, dose-dependent urinary Phe and glutamine increase; eGFR dip observed.","MZE782 Phase 2 trials in PKU and CKD expected to initiate in 2026; MZE829 HORIZON topline data by Q1 2026.","Appointed Hervé Hoppenot as chairman and Misbah Tahir as CFO in Sep/Oct 2025."],"consensus_eps_estimate":-0.7227,"consensus_eps_actual":-2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126283,"accession_number":"0001193125-25-230926","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Maze appoints ex-Incyte CEO Hervé Hoppenot as Chairman, effective Oct 6","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hervé Hoppenot appointed Class II director and Chairman of the Board, succeeding Charles Homcy, who remains a director.","Hoppenot served as Incyte CEO (2014-2025) and Chairman (2015-2025); also on boards of Bicycle Therapeutics and Laboratoires Pierre Fabre.","Receives pro rata portions of $40k director retainer and $30k Chairman retainer; granted option for 36,000 shares vesting over 36 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143030,"accession_number":"0001193125-25-200760","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Maze raises $150M at premium; Phase 1 MZE782 data positive, Phase 2 in 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Oversubscribed private placement of $150M gross proceeds at $16.25/share (premium to last close), closed Sept 12.","Issued 4M shares and 5.23M pre-funded warrants; investors include Frazier, Deep Track, Janus Henderson, others.","Phase 1 MZE782 in 112 healthy volunteers: 42-fold urinary Phe excretion, no SAEs, well tolerated.","Dose-dependent eGFR dip similar to SGLT2 inhibitors observed; plans for Phase 2 in PKU and CKD in 2026.","Proceeds to advance MZE829 in APOL1 kidney disease, MZE782 Phase 2, Compass platform, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143029,"accession_number":"0001193125-25-193353","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Maze Therapeutics appoints Misbah Tahir as CFO, effective Sep 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Misbah Tahir appointed CFO, previously CFO of IGM Biosciences (Jan 2019–Aug 2025).","Annual base salary of $500,000, discretionary bonus up to 40% of base salary.","One-time sign-on bonus of $50,000 (clawback if service <1 year) and option for 325,000 shares.","Option vests 25% on first anniversary, then 1/48th monthly; severance includes 9 months base salary plus benefits.","Enhanced severance on termination without cause or for good reason within 3 months before/12 months after change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143028,"accession_number":"0000950170-25-107299","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maze Therapeutics reports Q2 2025 net loss of $33.7M, cash $264.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.7M in Q2 2025 vs net income of $139.1M in Q2 2024 (prior year had $165M license revenue).","Cash and cash equivalents $264.5M as of June 30, 2025 vs $196.8M at Dec 31, 2024; runway into H2 2027.","R&D expenses increased to $28.1M in Q2 2025 from $19.5M in Q2 2024 due to clinical trial costs.","MZE782 Phase 1 proof-of-mechanism data expected Q3 2025; MZE829 Phase 2 HORIZON data expected Q1 2026.","No license revenue recognized in Q2 2025."],"consensus_eps_estimate":-0.8731,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161122,"accession_number":"0000950170-25-071357","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maze Therapeutics Q1 net loss $32.8M; cash $294.4M; MZE829/MZE782 milestones reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents: $294.4M at March 31, 2025, up from $196.8M at Dec 31, 2024; runway into H2 2027.","Net loss of $32.8M for Q1 2025, vs $32.5M in Q1 2024; R&D expenses $27.6M (up from $21.9M).","MZE829 Phase 2 HORIZON trial enrolling APOL1 kidney disease patients; initial proof-of-concept data expected Q1 2026.","MZE782 Phase 1 healthy volunteer trial ongoing; initial biomarker data expected Q3 2025.","Cash increase largely from IPO proceeds; no revenue reported (clinical-stage biotech)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179299,"accession_number":"0000950170-25-047207","cik":1842295,"company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Maze Therapeutics: Q4 net loss $29.6M, FY net income $52.2M on $167.5M license revenue; cash runway into H2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $29.6M vs $26.6M loss a year ago; FY net income $52.2M vs $100.4M loss in 2023.","Cash and cash equivalents $196.8M as of Dec 31, 2024, up from $29.2M; combined with Feb 2025 IPO proceeds of $140M provides runway into H2 2027.","License revenue of $167.5M in FY2024 primarily from $150M upfront from Shionogi for MZE001.","Phase 2 HORIZON trial of MZE829 for AKD dosing patients; initial data expected Q1 2026.","Phase 1 trial of MZE782 ongoing; initial data including proof-of-mechanism expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1452536322.5053744,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}